Advertisement

Topics

Targetted medicine to reduce melanoma mutational burden

08:20 EDT 6 Sep 2016 | ecancermedicalscience

Prof McArthur speaks with ecancer at WCCS 2016 about targetted medicine to reduce melanoma mutational burden, with specific focus on the BRIM trials of cobimetinib and vemurafinib. He outlines the expansion of personalised therapy and genotyping for...

Original Article: Targetted medicine to reduce melanoma mutational burden

NEXT ARTICLE

More From BioPortfolio on "Targetted medicine to reduce melanoma mutational burden"

Quick Search
Advertisement
 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...